a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc)

April 2013

You'll hear more about a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc).

New evidence suggests about one more case of acute pancreatitis for every 50 diabetes patients using these drugs for up to 2 years.

These incretin mimetics might cause inflammation that could lead to acute pancreatitis...and possibly pancreatic cancer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote